Last reviewed · How we verify
LY2189265
LY2189265 is a long-acting GLP-1 receptor agonist that mimics glucagon-like peptide-1 to improve blood glucose control by stimulating insulin secretion and reducing glucagon release.
LY2189265 is a long-acting GLP-1 receptor agonist that mimics glucagon-like peptide-1 to improve blood glucose control by stimulating insulin secretion and reducing glucagon release. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | LY2189265 |
|---|---|
| Also known as | Dulaglutide, Trulicity, dulaglutide |
| Sponsor | Eli Lilly and Company |
| Drug class | GLP-1 receptor agonist |
| Target | GLP-1R |
| Modality | Biologic |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
The drug binds to and activates GLP-1 receptors on pancreatic beta cells, enhancing glucose-dependent insulin secretion. It also slows gastric emptying and promotes satiety, contributing to weight loss. The extended half-life formulation allows for less frequent dosing compared to shorter-acting GLP-1 agonists.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Hypoglycemia
- Headache
Key clinical trials
- A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS) (PHASE3)
- A Study to Evaluate the Effect of Fasting Duration and Dulaglutide (LY2189265) Withholding on Gastric Retention in Participants With Type 2 Diabetes Mellitus (PHASE1)
- A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (PHASE3)
- A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH) (PHASE4)
- A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus in India (PHASE4)
- A Study of LY3493269 in Participants With Type 2 Diabetes (PHASE1)
- A Study of Two Doses of Dulaglutide (LY2189265) in Japanese Patients With Type 2 Diabetes (PHASE3)
- A Study of LY3457263 Alone and in Combination With Dulaglutide (LY2189265) in Participants With Type 2 Diabetes (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LY2189265 CI brief — competitive landscape report
- LY2189265 updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI